Your Account
Drug Management of Prostate Cancer
(To see other currencies, click on price)
Add to basket  


Main description:

Prostate cancer is the most common noncutaneous prostate cancer. Research has revealed several distinct malignancy and the second leading cause of cancer mechanisms of castration-resistant disease that may deaths among men in the United States. It is a critical converge in patients with disease progression on public health problem and remains incurable in the ADT. Many approaches are currently being evaluated metastatic setting with mortality that usually occurs as to improve the treatment of this condition and these a result of castration-resistant disease. fndings have identifed several potential targets for Since Huggins and Hodges’ report of the dra- therapeutic intervention. These include drugs that are matic clinical effects of suppressing serum testos- more active or less toxic chemotherapy agents; drugs terone levels in men with advanced prostate cancer that induce androgen deprivation; drugs that target in 1941, hormone therapy (also called androgen the androgen receptor and/or androgen synthesis; deprivation therapy [ADT]) has become widely drugs that target specifc pathways, including ang- accepted as the mainstay of therapy for the treat- genesis and tyrosine kinase inhibitors, endothelin ment of advanced prostate cancer. ADT combined antagonists and matrix metalloproteinase inhibitors; with radiation therapy is a standard of care in the and immunologic approaches. Many of these agents treatment of men with locally advanced prostate seem promising and the rationale and effcacy of cancer on the basis of evidence that shows improved these emerging therapies remain to be validated in survival. The role of ADT in the management of future clinical trials.


Provides a comprehensive guide to the spectrum of emerging pharmacologic agents

Covers both standard of care and investigational therapeutics

Written by recognized international authorities in the field

Well suited for clinicians actively involved in the medical management of patients with prostate cancer

Back cover:

This book is a comprehensive, concise summary of the pharmacological treatments of prostate cancer. It is an authoritative and up-to-date reference on therapeutic options involving both standard of care and investigational agents. The chapters describe state of the art information on Hormone Therapy, Chemotherapy, Angiogenesis, Therapy for Bone Metastases, Immunotherapy, Prevention, and Drug Development. Drug Management of Prostate Cancer is an excellent resource for medical oncologists, trainees, researchers, and members of the pharmaceutical industry


Section One Hormone Therapy

Chapter 1 Cell Biology of Prostate Cancer and Molecular Targets
Martin E. Gleave, Michael E. Cox, Yuzhuo Wang

Chapter 2 Luteinizing Hormone-Releasing Hormone (Lh-Rh) and its Agnostic, Antagonistic and Targeted Cytotoxic Analogs in Prostate Cancer
Andrew V. Schally and Norman L. Block

Chapter 3 Nuclear Receptor Coregulators: Promising Therapeutic Targets for the Treatment of Prostate Cancer
Hannelore V. Heemers and Donald J. Tindall

Chapter 4 Androgens and Prostate Cancer
Douglas K. Price and Ann W. Hsing

Chapter 5 Androgen Receptor Biology in Prostate Cancer
Edward P. Gelmann

Chapter 6 Androgen Receptor Antagonists
Howard C. Shen, Mary-Ellen Taplin, Steven P. Balk

Chapter 7 5 alpha Reductase Inhibitors in Prostate Cancer
Zoran Culig

Chapter 8 Adrenolytic Therapies in Castration Resistant Prostate Cancer
Terence W. Friedlander and Charles J. Ryan

Chapter 9 Androgen Deprivation Therapy
Nima Sharifi

Chapter 10 Pharmacogenetics of the Androgen Metabolic Pathway
Francine Zanchetta Coehlo Marques and Juergen Reichardt

Section Two Chemotherapy

Chapter 11 Mitoxantrone
Patricia Halterman, Nicholas J. Vogelzang, Alireza Farabishahadel, Oscar B. Goodman, Jr.

Chapter 12 Docetaxel
Courtney K. Phillips and Daniel P. Petrylak

Chapter 13 Beyond Docetaxel: Emerging Agents in the Treatment of Advanced Prostate Cancer
Jonathan Rosenberg

Chapter 14 Platinum Agents in Prostate Cancer
Ashley Brick, Junyang Niu, Jiaoti Huang, William K. Oh

Chapter 15 Clinical Pharmacology and Pharmacogenetics of Chemotherapy in Prostate Cancer
Tristan M. Sissung and William D. Figg

Chapter 16 Microtubule Targeting Agents
Antonio Tito Fojo and David E. Adelberg

Section Three Angiogenesis

Chapter 17 Principles of Antiangiogenic Therapy
Cindy H. Chau and William D. Figg

Chapter 18 Bevacizumab in Advanced Prostate Cancer
Aymen A. Elfiky and William Kevin Kelly

Chapter 19 Thalidomide and Analogs
Erin R. Gardner, Giuseppe Di Lorenzo, and William D. Figg

Chapter 20 Investigational Angiogenesis Inhibitors
Jeanny B. Aragon-Ching, William Dahut, MD

Chapter 21 Pharmacogenetics of Angiogenesis
Guido Bocci, Giuseppe Pasqualetti, Antonello Di Paolo, Francesco Crea, Mario Del Tacca, Romano Danesi

Section Four Bone Metastasis

Chapter 22 Pathophysiology of Prostate Cancer Bone Metastasis
Evan T. Keller and Christopher L. Hall

Chapter 23 Radiopharmaceuticals
Oliver Sartor and Damerla R. Venugopal

Chapter 24 Bisphosphonates for Prevention and Treatment of Bone Metastases
Philip J. Saylor and Matthew R. Smith

Chapter 25 Endothelin Receptors as Therapeutic Targets in Castrate Resistant Prostate Cancer
Joel B. Nelson

Chapter 26 Calcitriol and Vitamin D Analogs
Ana R. Jensen, Russell Z. Szmulewitz, Tomasz M. Beer, Edwin M. Posadas

Chapter 27 Cancer Immunology, Immunotherapeutics and Vaccine Approaches
Ravi A. Madan, James L. Gulley, Jackie Celestin, Philip M. Arlen, Jeffrey Schlom

Chapter 28 Sipuleucel-T (APC8015): Active Cellular Immunotherapy for Advanced Metastatic Castrate-Resistant Prostate Cancer
Celestia S. Higano and Mark W. Frohlich

Chapter 29 GM-CSF Genes Transduced Prostate Cancer Vaccines: GVAX
Lalit R. Patel and Jonathan W. Simons

Chapter 30 CTLA-4 Blockade for Prostate Cancer Treatment
Andrea L. Harzstark and Lawrence Fong

Section Five – Prevention

Chapter 31 Prostate Cancer Chemoprevention Strategies
Howard L. Parnes, Margaret G. House, Joseph A. Tangrea

Chapter 32 Diet and Prostate Cancer Incidence, Recurrence, and Progression Risk
June M. Chan and Erin L. Richman

Chapter 33 Inflammation as a Target in Prostate Cancer
Marshall Scott Lucia, James R. Lambert, Elizabeth A. Platz, Angelo M. De Marzo

Section Six Drug Development

Chapter 34 Challenges for the Development of New Agents in Prostate Cancer
Ajjai S. Alva, Deborah A. Bradley, Maha Hussain

Chapter 35 FDA Approval of Prostate Cancer


ISBN-13: 9781603278294
Publisher: Springer (Springer New York)
Publication date: September, 2010
Pages: 448

Subcategories: Oncology, Urology